The first human clinical trial was unsuccessful. Banting was insufficiently qualified to participate and felt sidelined. By the winter of 1922, he was certain that all Macleod's colleagues were conspiring against him. Collip threatened to leave because of the strained atmosphere, but the encouragement of others who saw the potential of their research prevented escalation of the conflict. In January 1922, the team performed the first successful clinical trial, on 14-year-old Leonard Thompson, and it was soon followed by others. Although all the team members were listed as co-authors of their publications, Banting still felt overlooked, because Macleod took over the coordination of clinical trials and the acquisition of larger amounts of extract. Macleod's presentation at a meeting of the Association of American Physicians in Washington, D.C., on 3 May 1922 received a standing ovation, but Banting and Best refused to participate in protest. At that time, demonstrations of the method's efficiency drew huge public interest, because the effect on patients, especially children, who until then were bound to die, seemed almost miraculous. The pharmaceutical company Eli Lilly & Co. took over mass production, but without an exclusive license, as the patent was transferred to the British Medical Research Council to prevent exploitation.